Australian anti-cancer company completes $2.6 million placement Australian monoclonal antibody company, DISEASE FIGHTING CAPABILITY Therapeutics Limited , today said it completed an exclusive placement to improve $2 million from brand-new and existing personal and institutional investors in Australia levitra wiki read more . Investors have decided to buy 5,200,000 shares in the business at a cost of $0.6 million. DISEASE FIGHTING CAPABILITY Therapeutics Chairman, Dr. Related StoriesCornell biomedical engineers develop 'super organic killer cells' to destroy tumor cells in lymph nodesCrucial modification in single DNA bottom predisposes children to intense type of cancerNew antenna-like gadget makes breast cancer medical procedures less complicated for surgeonsDr.